Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Blood (2007) 110 (10): 3557–3560.

https://doi.org/10.1182/blood-2006-08-036947

Published: 2007

Includes: Supplemental data

Journal Articles

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

George Mulligan, Constantine Mitsiades, Barb Bryant, Fenghuang Zhan, Wee J. Chng, Steven Roels, Erik Koenig, Andrew Fergus, Yongsheng Huang, Paul Richardson, William L. Trepicchio, Annemiek Broyl, Pieter Sonneveld, John D. Shaughnessy, Jr, P. Leif Bergsagel, David Schenkein, Dixie-Lee Esseltine, Anthony Boral, Kenneth C. Anderson

Blood (2006) 109 (8): 3177–3188.

https://doi.org/10.1182/blood-2006-09-044974

Published: 2006

Includes: Supplemental data

Journal Articles

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

Belén Blanco, José A. Pérez-Simón, Luis I. Sánchez-Abarca, Xonia Carvajal-Vergara, Juan Mateos, Belén Vidriales, Natalia López-Holgado, Patricia Maiso, Mercedes Alberca, Eva Villarón, David Schenkein, Atanasio Pandiella, Jesús San Miguel

Blood (2006) 107 (9): 3575–3583.

https://doi.org/10.1182/blood-2005-05-2118

Published: 2006

Journal Articles

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

Eyal C. Attar, MD, Daniel J. De Angelo, MD, PhD, Andres Sirulnik, MD, PhD, Martha Wadleigh, MD, Karen K. Ballen, MD, Kenneth B. Miller, MD, Ilene Galinsky, Donna Neuberg, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Richard M. Stone, MD, Philip C. Amrein, MD

Blood (2005) 106 (11): 2782.

https://doi.org/10.1182/blood.V106.11.2782.2782

Published: 2005

Journal Articles

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

John Gerecitano, MD, PhD, Andre Goy, MD, Barbara MacGregor-Cortelli, OCN, Ellen Neylon, John Wright, MD, PhD, Dixie Esseltine, MD, David Schenkein, MD, Mithat Gonen, PhD, Owen A. O’Connor, MD, PhD

Blood (2005) 106 (11): 3334.

https://doi.org/10.1182/blood.V106.11.3334.3334

Published: 2005

Journal Articles

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Rakesh Popat, MBBS, Heather E. Oakervee, MRCPath, Nicola Curry, MBBS, Nicola Foot, BSc, Curly Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David Schenkein, MD, Dixie-Lee Esseltine, MD, Jamie D. Cavenagh, MD

Blood (2005) 106 (11): 2554.

https://doi.org/10.1182/blood.V106.11.2554.2554

Published: 2005

Journal Articles

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

Paul Gerard Guy Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, Kenneth C. Anderson, for the SUMMIT Investigators

Blood (2005) 106 (9): 2977–2981.

https://doi.org/10.1182/blood-2005-02-0691

Published: 2005

Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD

Blood (2004) 104 (11): 1386.

https://doi.org/10.1182/blood.V104.11.1386.1386

Published: 2004

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

Journal Articles

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.

Sundar Jagannath, MD, Durie Brian, MD, Jeffrey L. Wolf, MD, Elber Camacho, MD, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, MD, Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, David Schenkein, MD

Blood (2004) 104 (11): 333.

https://doi.org/10.1182/blood.V104.11.333.333

Published: 2004

Journal Articles

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Teru Hideshima, MD, PhD, Pierfrancesco Tassone, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Makoto Hamasaki, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, David Schenkein, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2351.

https://doi.org/10.1182/blood.V104.11.2351.2351

Published: 2004

Journal Articles

Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.

Stefan Faderl, MD, Kanti R. Rai, MD, John Gribben, MD, Ian Flinn, MD, John C. Byrd, MD, David McConkey, PhD, David Schenkein, MD, Dixie Esseltine, MD, Mary L. Browning, RN, Michael J. Keating, MD

Blood (2004) 104 (11): 4841.

https://doi.org/10.1182/blood.V104.11.4841.4841

Published: 2004

Journal Articles

Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction

Todd F. Roberts, Kellie Sprague, David Schenkein, Kenneth B. Miller, Valerie Relias

Blood (2000) 96 (12): 4000–4001.

https://doi.org/10.1182/blood.V96.12.4000

Published: 2000

NARROW

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.

Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only